File No. BC45300-1US Serial No.: 10/650,608

Page 2 of 3

REMARKS

Applicants submit herewith a PTO Form 1449 listing the declaration filed by GSK employee Anthony Pilorget, together with a copy of the declaration, and a Request for Continued Examination. On September 21, 2009 Applicants disclosed to the USPTO the declaration of Anthony Pilorget submitted by Applicants in the European national phase entry of the PCT application from which the present application claims priority. Applicants submitted a copy of the declaration along with a Form 1449 listing the declaration. The Examiner marked the 1449 form, indicating that the declaration was considered, but would not be printed upon the face of the allowed patent because the Form 1449 did not list page numbers for the declaration. The case was then allowed by the Examiner.

Accordingly, Applicants submit herewith a Form 1449 listing the declaration by Anthony Pilorget with the declaration page numbers, together with a copy of the declaration as made publicly available on June 26, 2009 in the file history of the European Patent Application No. 01929345. Applicants respectfully request that the Examiner mark the 1449 to indicate that the declaration is (i) considered and (ii) to be published on the face of the granted patent.

Summary of 24 Feb 2010 Telephonic Interview Between the Undersigned and Examiner Davis

The undersigned contacted Examiner Davis to inquire whether the declaration discussed above could be listed on the face of the granted patent if Applicants provided page numbers for the declaration. Examiner Davis indicated that it would be included if page numbers were provided. Because the issue fee is due shortly, it was agreed that the best course of action would be the filing of a RCE and Form 1449 as described above in order to allow the case and thereby include the declaration among the listed references in

File No. BC45300-1US Serial No.: 10/650,608

Page 3 of 3

the granted patent.

The Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted.

/Eric J. Kron/ Eric J. Kron Attorney for Applicant Registration No. 45,941

Date: 26 Feb 2010
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398

Phone: 919-483-8961 Facsimile: 919-483-7988